Adverse Events Module

Adverse Events Module

For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.

Adverse Events Module path is as follows:

Study -> Results Section -> Adverse Events Module -> Event Groups

Study -> Results Section -> Adverse Events Module -> Serious Events

Study -> Results Section -> Adverse Events Module -> Other Events

Adverse Events Module


Ignite Creation Date: 2025-12-24 @ 2:58 PM
Ignite Modification Date: 2025-12-25 @ 1:23 PM
NCT ID: NCT01226459
Description: None
Frequency Threshold: 2.0
Time Frame: None
Study: NCT01226459
Study Brief: Clinical Trial in Females for Female Pattern Hair Loss
Event Groups(If Any):

Event Groups

Title Description Deaths # Affected Deaths # At Risk Serious # Affected Serious # At Risk Other # Affected Other # At Risk View
Vehicle Foam Vehicle Topical Foam Vehicle Topical Foam: Dosage Form: Vehicle Topical Foam applied to the scalp; Dosage: half a cap, equivalent to 1 g of foam; Frequency: once every day; Duration: 24 weeks None None 4 201 57 201 View
Minoxidil Foam 5% Minoxidil Topical Foam 5% Minoxidil Topical Foam: Dosage Form: 5% Minoxidil Topical Foam applied to the scalp; Dosage: half a cap, equivalent to 1 g of foam; Frequency: once every day; Duration: 24 weeks None None 6 203 63 203 View
Serious Events(If Any):

Serious Events

Term Type Organ System Vocab View
Ovarian Cancer SYSTEMATIC_ASSESSMENT Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA 14.1 View
Ovarian Neoplasm SYSTEMATIC_ASSESSMENT Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA 14.1 View
Uterine Leiomyoma SYSTEMATIC_ASSESSMENT Nervous system disorders MedDRA 14.1 View
Atrial Fibrillation SYSTEMATIC_ASSESSMENT Cardiac disorders MedDRA 14.1 View
Cardiovascular Disorder SYSTEMATIC_ASSESSMENT Cardiac disorders MedDRA 14.1 View
Cor Pulmonale Acute SYSTEMATIC_ASSESSMENT Cardiac disorders MedDRA 14.1 View
Asthenia SYSTEMATIC_ASSESSMENT General disorders MedDRA 14.1 View
Fatigue SYSTEMATIC_ASSESSMENT General disorders MedDRA 14.1 View
Gastritis SYSTEMATIC_ASSESSMENT Gastrointestinal disorders MedDRA 14.1 View
Dehydration SYSTEMATIC_ASSESSMENT Metabolism and nutrition disorders MedDRA 14.1 View
Osteoarthritis SYSTEMATIC_ASSESSMENT Musculoskeletal and connective tissue disorders MedDRA 14.1 View
Memory Impairment SYSTEMATIC_ASSESSMENT Nervous system disorders MedDRA 14.1 View
Mental Status Changes SYSTEMATIC_ASSESSMENT Psychiatric disorders MedDRA 14.1 View
Post-Traumatic Stress Disorder SYSTEMATIC_ASSESSMENT Psychiatric disorders MedDRA 14.1 View
Renal Failure SYSTEMATIC_ASSESSMENT Renal and urinary disorders MedDRA 14.1 View
Hypertensive Crisis SYSTEMATIC_ASSESSMENT Vascular disorders MedDRA 14.1 View
Other Events(If Any):

Other Events

Term Type Organ System Vocab View
Back Pain SYSTEMATIC_ASSESSMENT Musculoskeletal and connective tissue disorders MedDRA 14.1 View
Nasopharyngitis SYSTEMATIC_ASSESSMENT Infections and infestations MedDRA 14.1 View
Upper Respiratory Tract Infection SYSTEMATIC_ASSESSMENT Infections and infestations MedDRA 14.1 View
Sinusitis SYSTEMATIC_ASSESSMENT Infections and infestations MedDRA 14.1 View
Gastroenteritis SYSTEMATIC_ASSESSMENT Infections and infestations MedDRA 14.1 View
Urinary Tract Infection SYSTEMATIC_ASSESSMENT Infections and infestations MedDRA 14.1 View
Weight Increased SYSTEMATIC_ASSESSMENT Investigations MedDRA 14.1 View
Headache SYSTEMATIC_ASSESSMENT Nervous system disorders MedDRA 14.1 View
Hypertension SYSTEMATIC_ASSESSMENT Vascular disorders MedDRA 14.1 View